Vaccine Conjugate Industry Research Report 2025

Summary

According to APO Research, the global Vaccine Conjugate market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Vaccine Conjugate is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Vaccine Conjugate is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Vaccine Conjugate is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Vaccine Conjugate include Bharat Biotech, Beijing Minhai Biotechnology, Beijing Xiangrui Biological Products, Chengdu Olymvax Biopharmaceuticals, GSK, Pfizer, CanSinoBIO, Royal (Wuxi) Bio-Pharmaceutical and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Vaccine Conjugate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaccine Conjugate.

The report will help the Vaccine Conjugate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Vaccine Conjugate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vaccine Conjugate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Vaccine Conjugate Segment by Company

Bharat Biotech
Beijing Minhai Biotechnology
Beijing Xiangrui Biological Products
Chengdu Olymvax Biopharmaceuticals
GSK
Pfizer
CanSinoBIO
Royal (Wuxi) Bio-Pharmaceutical
Merck
Sanofi
Walvax Biotechnology
Zhifei Biologic
Vaccine Conjugate Segment by Type

Hib Vaccine
Pneumococcal Vaccine
Meningococcal Vaccine
Others
Vaccine Conjugate Segment by Application

Children
Adult
Vaccine Conjugate Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East Middle East & Africa
Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Conjugate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vaccine Conjugate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vaccine Conjugate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vaccine Conjugate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Vaccine Conjugate Market Size (2020-2031)
2.2.2 Global Vaccine Conjugate Sales (2020-2031)
2.2.3 Global Vaccine Conjugate Market Average Price (2020-2031)
2.3 Vaccine Conjugate by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Hib Vaccine
2.3.3 Pneumococcal Vaccine
2.3.4 Meningococcal Vaccine
2.3.5 Others
2.4 Vaccine Conjugate by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Children
2.4.3 Adult
3 Market Competitive Landscape by Manufacturers
3.1 Global Vaccine Conjugate Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Vaccine Conjugate Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Vaccine Conjugate Revenue of Manufacturers (2020-2025)
3.4 Global Vaccine Conjugate Average Price by Manufacturers (2020-2025)
3.5 Global Vaccine Conjugate Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Vaccine Conjugate, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Vaccine Conjugate, Product Type & Application
3.8 Global Manufacturers of Vaccine Conjugate, Established Date
3.9 Global Vaccine Conjugate Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Bharat Biotech
4.1.1 Bharat Biotech Company Information
4.1.2 Bharat Biotech Business Overview
4.1.3 Bharat Biotech Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Bharat Biotech Vaccine Conjugate Product Portfolio
4.1.5 Bharat Biotech Recent Developments
4.2 Beijing Minhai Biotechnology
4.2.1 Beijing Minhai Biotechnology Company Information
4.2.2 Beijing Minhai Biotechnology Business Overview
4.2.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio
4.2.5 Beijing Minhai Biotechnology Recent Developments
4.3 Beijing Xiangrui Biological Products
4.3.1 Beijing Xiangrui Biological Products Company Information
4.3.2 Beijing Xiangrui Biological Products Business Overview
4.3.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio
4.3.5 Beijing Xiangrui Biological Products Recent Developments
4.4 Chengdu Olymvax Biopharmaceuticals
4.4.1 Chengdu Olymvax Biopharmaceuticals Company Information
4.4.2 Chengdu Olymvax Biopharmaceuticals Business Overview
4.4.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio
4.4.5 Chengdu Olymvax Biopharmaceuticals Recent Developments
4.5 GSK
4.5.1 GSK Company Information
4.5.2 GSK Business Overview
4.5.3 GSK Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.5.4 GSK Vaccine Conjugate Product Portfolio
4.5.5 GSK Recent Developments
4.6 Pfizer
4.6.1 Pfizer Company Information
4.6.2 Pfizer Business Overview
4.6.3 Pfizer Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Pfizer Vaccine Conjugate Product Portfolio
4.6.5 Pfizer Recent Developments
4.7 CanSinoBIO
4.7.1 CanSinoBIO Company Information
4.7.2 CanSinoBIO Business Overview
4.7.3 CanSinoBIO Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.7.4 CanSinoBIO Vaccine Conjugate Product Portfolio
4.7.5 CanSinoBIO Recent Developments
4.8 Royal (Wuxi) Bio-Pharmaceutical
4.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
4.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
4.8.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio
4.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
4.9 Merck
4.9.1 Merck Company Information
4.9.2 Merck Business Overview
4.9.3 Merck Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Merck Vaccine Conjugate Product Portfolio
4.9.5 Merck Recent Developments
4.10 Sanofi
4.10.1 Sanofi Company Information
4.10.2 Sanofi Business Overview
4.10.3 Sanofi Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Sanofi Vaccine Conjugate Product Portfolio
4.10.5 Sanofi Recent Developments
4.11 Walvax Biotechnology
4.11.1 Walvax Biotechnology Company Information
4.11.2 Walvax Biotechnology Business Overview
4.11.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Walvax Biotechnology Vaccine Conjugate Product Portfolio
4.11.5 Walvax Biotechnology Recent Developments
4.12 Zhifei Biologic
4.12.1 Zhifei Biologic Company Information
4.12.2 Zhifei Biologic Business Overview
4.12.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Zhifei Biologic Vaccine Conjugate Product Portfolio
4.12.5 Zhifei Biologic Recent Developments
5 Global Vaccine Conjugate Market Scenario by Region
5.1 Global Vaccine Conjugate Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Vaccine Conjugate Sales by Region: 2020-2031
5.2.1 Global Vaccine Conjugate Sales by Region: 2020-2025
5.2.2 Global Vaccine Conjugate Sales by Region: 2026-2031
5.3 Global Vaccine Conjugate Revenue by Region: 2020-2031
5.3.1 Global Vaccine Conjugate Revenue by Region: 2020-2025
5.3.2 Global Vaccine Conjugate Revenue by Region: 2026-2031
5.4 North America Vaccine Conjugate Market Facts & Figures by Country
5.4.1 North America Vaccine Conjugate Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Vaccine Conjugate Sales by Country (2020-2031)
5.4.3 North America Vaccine Conjugate Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Vaccine Conjugate Market Facts & Figures by Country
5.5.1 Europe Vaccine Conjugate Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Vaccine Conjugate Sales by Country (2020-2031)
5.5.3 Europe Vaccine Conjugate Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Vaccine Conjugate Market Facts & Figures by Country
5.6.1 Asia Pacific Vaccine Conjugate Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Vaccine Conjugate Sales by Country (2020-2031)
5.6.3 Asia Pacific Vaccine Conjugate Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Vaccine Conjugate Market Facts & Figures by Country
5.7.1 South America Vaccine Conjugate Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Vaccine Conjugate Sales by Country (2020-2031)
5.7.3 South America Vaccine Conjugate Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Vaccine Conjugate Market Facts & Figures by Country
5.8.1 Middle East and Africa Vaccine Conjugate Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Vaccine Conjugate Sales by Country (2020-2031)
5.8.3 Middle East and Africa Vaccine Conjugate Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Vaccine Conjugate Sales by Type (2020-2031)
6.1.1 Global Vaccine Conjugate Sales by Type (2020-2031) & (K Units)
6.1.2 Global Vaccine Conjugate Sales Market Share by Type (2020-2031)
6.2 Global Vaccine Conjugate Revenue by Type (2020-2031)
6.2.1 Global Vaccine Conjugate Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Vaccine Conjugate Revenue Market Share by Type (2020-2031)
6.3 Global Vaccine Conjugate Price by Type (2020-2031)
7 Segment by Application
7.1 Global Vaccine Conjugate Sales by Application (2020-2031)
7.1.1 Global Vaccine Conjugate Sales by Application (2020-2031) & (K Units)
7.1.2 Global Vaccine Conjugate Sales Market Share by Application (2020-2031)
7.2 Global Vaccine Conjugate Revenue by Application (2020-2031)
7.2.1 Global Vaccine Conjugate Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Vaccine Conjugate Revenue Market Share by Application (2020-2031)
7.3 Global Vaccine Conjugate Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Vaccine Conjugate Value Chain Analysis
8.1.1 Vaccine Conjugate Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Vaccine Conjugate Production Mode & Process
8.2 Vaccine Conjugate Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Vaccine Conjugate Distributors
8.2.3 Vaccine Conjugate Customers
9 Global Vaccine Conjugate Analyzing Market Dynamics
9.1 Vaccine Conjugate Industry Trends
9.2 Vaccine Conjugate Industry Drivers
9.3 Vaccine Conjugate Industry Opportunities and Challenges
9.4 Vaccine Conjugate Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings